Search

Your search keyword '"E Reyes"' showing total 1,373 results

Search Constraints

Start Over You searched for: Author "E Reyes" Remove constraint Author: "E Reyes" Database OpenAIRE Remove constraint Database: OpenAIRE
1,373 results on '"E Reyes"'

Search Results

1. Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+

2. Move Up, Live Up: Dance Activities as a Way of Motivating Students Participating in Progressive Limited Face-to-face Classes

4. Genomic Evidence Suggests Viral Persistence of SARS-CoV-2 for 386 Days in Health Worker: A Case Report from Santiago of Chile

6. Genetic diversity and relatedness inferred from microsatellite loci as a tool for broodstock management of fine flounder Paralichthys adspersus

8. Handy EKG: a low-cost 3-lead electrocardiograph for primary care

11. Caracterización y estudio preliminar de lixiviación de plata contenida en un concentrado de plomo

12. Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers

13. Canvas Model as a Tool for Research Projects: A Theoretical Approach

14. Supplementary Figure 6 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases

18. Data from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases

21. Supplementary Figure 2 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases

24. Supplementary Table from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development

28. Supplementary Figure 6 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development

30. Supplementary Figure 2 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development

31. Data from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development

33. Supplementary Figure 6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

34. Supplementary Figure 2 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

35. Supplementary Figure 1 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

36. Supplementary Figure 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

37. Supplementary Figure Legends 1-6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

38. Supplementary Figure 3 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

39. Supplementary Tables 1 - 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

40. Supplementary Figure 5 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

41. Relationship between Leaf Degradation and Pore Water Chemistry in Two Mangrove Forests of Southeastern Mexico

42. Posttraumatic Stress Disorder and Substance Misuse Among Black Emerging Adults: The Influence of Social Support

43. Analysis by real‐time PCR of five transport and conservation mediums of nasopharyngeal swab samples to COVID‐19 diagnosis in Santiago of Chile

44. Control y prevención de nematodosis en pequeños rumiantes: antecedentes, retos y perspectivas en México

45. Genome-wide CRISPR screen reveals genetic modifiers of Ca2+-mediated cell death

47. ÉTUDE NUMÉRIQUE DE LA COLLECTE DE PARTICULES D'AÉROSOL PAR DES GOUTTES EN CHUTE

Catalog

Books, media, physical & digital resources